{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T15:20:50Z","timestamp":1780932050159,"version":"3.54.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T00:00:00Z","timestamp":1584144000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T00:00:00Z","timestamp":1584144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>We performed a pooled analysis of the COMPARZ study assessing efficacy and safety of pazopanib versus sunitinib in treatment-na\u00efve Chinese patients with locally advanced and\/or metastatic renal cell carcinoma (a\/mRCC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In the COMPARZ study, patients were randomized (1:1) to receive pazopanib 800\u2009mg once daily (QD) continuously or sunitinib 50\u2009mg QD in 6-week\u2009cycles (4\u2009weeks on, 2\u2009weeks off). The primary endpoint was progression-free survival (PFS); secondary endpoints included overall response rate (ORR), overall survival (OS), and safety. PFS and ORR were assessed by independent review committee (IRC) and local investigators.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 209 Chinese patients (pazopanib, [<jats:italic>n<\/jats:italic>\u2009=\u2009109] and sunitinib, [<jats:italic>n<\/jats:italic>\u2009=\u2009100]), 155 (74%) were males and median age was 57\u2009years (range, 18\u201379). Median PFS was 13.9\u2009months for pazopanib versus 14.3\u2009months for sunitinib per investigator assessment and 8.3\u2009months in both arms per IRC assessment; PFS hazard ratio was 1.17 (investigator) and 0.99 (IRC). Median OS was not reached in pazopanib arm and was 29.5\u2009months in sunitinib arm. ORR was significantly higher in pazopanib arm versus sunitinib arm (investigator: 41% versus 23% [<jats:italic>P<\/jats:italic>\u2009=\u20090.0052]; IRC: 35% versus 20% [<jats:italic>P<\/jats:italic>\u2009=\u20090.0203]). Pazopanib was generally well tolerated in Chinese patients with a\/mRCC. Most frequent AEs in the pazopanib arm were diarrhea and hair color changes whereas the most frequent AEs in the sunitinib arm were decreased platelets, decreased neutrophil count, and thrombocytopenia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The results of the pooled analysis were consistent with the overall population in the COMPARZ study, and confirmed similar PFS and OS of pazopanib and sunitinib in the Chinese patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>clinical trials.gov,<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00720941\">NCT00720941<\/jats:ext-link>(August 14, 2008) and<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01147822\">NCT01147822<\/jats:ext-link>(May 19, 2010).<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12885-020-6708-8","type":"journal-article","created":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T11:03:20Z","timestamp":1584183800000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies"],"prefix":"10.1186","volume":"20","author":[{"given":"Xinan","family":"Sheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhisong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinwan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiubao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingwei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shukui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangjian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binhui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,14]]},"reference":[{"key":"6708_CR1","doi-asserted-by":"crossref","unstructured":"Deveson KS. Renal cell carcinoma: treatment options. Br J Nurs. 2011;20(9):536-9.","DOI":"10.12968\/bjon.2011.20.9.536"},{"issue":"19","key":"6708_CR2","first-page":"279","volume":"3","author":"J Guo","year":"2015","unstructured":"Guo J, Ma J, Sun Y, Qin S, Ye D, Zhou F, et al. Chinese guidelines on the management of renal cell carcinoma (2015 edition). Ann Transl Med. 2015;3(19):279.","journal-title":"Ann Transl Med"},{"issue":"14","key":"6708_CR3","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1002\/cncr.30666","volume":"123","author":"XM Wan","year":"2017","unstructured":"Wan XM, Peng LB, Ma JA, Li YJ. Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectives. Cancer. 2017;123(14):2634\u201341.","journal-title":"Cancer"},{"issue":"4","key":"6708_CR4","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMra1601333","volume":"376","author":"TK Choueiri","year":"2017","unstructured":"Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376(4):354\u201366.","journal-title":"N Engl J Med"},{"key":"6708_CR5","first-page":"313","volume":"8","author":"X Tan","year":"2015","unstructured":"Tan X, Liu Y, Hou J, Cao G. Targeted therapies for renal cell carcinoma in Chinese patients: focus on everolimus. Onco Targets Ther. 2015;8:313\u201321.","journal-title":"Onco Targets Ther"},{"issue":"34","key":"6708_CR6","doi-asserted-by":"crossref","first-page":"36870","DOI":"10.18632\/oncotarget.4874","volume":"6","author":"H-L Zhang","year":"2015","unstructured":"Zhang H-L, Qin X-J, Wang H-K, Gu W-J, Ma C-G, Shi G-H, et al. Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study. Oncotarget. 2015;6(34):36870\u201383.","journal-title":"Oncotarget"},{"issue":"1","key":"6708_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12885-016-3016-4","volume":"17","author":"H-L Zhang","year":"2017","unstructured":"Zhang H-L, Sheng X-N, Li X-S, Wang H-K, Chi Z-H, He Z-S, et al. Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors. BMC Cancer. 2017;17(1):16.","journal-title":"BMC Cancer"},{"issue":"8","key":"6708_CR8","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722\u201331.","journal-title":"N Engl J Med"},{"issue":"8","key":"6708_CR9","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","volume":"10","author":"ME Gore","year":"2009","unstructured":"Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009;10(8):757\u201363.","journal-title":"Lancet Oncol"},{"issue":"5\u20136","key":"6708_CR10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1159\/000330361","volume":"80","author":"HS Kim","year":"2011","unstructured":"Kim HS, Hong MH, Kim K, Shin SJ, Ahn JB, Jeung HC, et al. Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. Oncology. 2011;80(5\u20136):395\u2013405.","journal-title":"Oncology"},{"issue":"8","key":"6708_CR11","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3760\/cma.j.issn.0366-6999.20132411","volume":"127","author":"Z He","year":"2014","unstructured":"He Z, Guo G, Zhang C, Li X, Fu W, Jin J, Zhang X, Zhou L. Efficacy of sunitinib in patients with metastatic renal cell carcinoma: initial experience in two Chinese centers. Chin Med J. 2014;127(8):1450\u20133.","journal-title":"Chin Med J"},{"issue":"10","key":"6708_CR12","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/jjco\/hyq073","volume":"40","author":"C Yoo","year":"2010","unstructured":"Yoo C, Kim JE, Lee JL, Ahn JH, Lee DH, Lee JS, et al. The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn J Clin Oncol. 2010;40(10):980\u20135.","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"6708_CR13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1743-7563.2012.01525.x","volume":"8","author":"A Zhou","year":"2012","unstructured":"Zhou A. Management of sunitinib adverse events in renal cell carcinoma patients: the Asian experience. Asia Pac J Clin Oncol. 2012;8(2):132\u201344.","journal-title":"Asia Pac J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-6708-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-6708-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-6708-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T05:23:28Z","timestamp":1722576208000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-6708-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,14]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6708"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-6708-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,14]]},"assertion":[{"value":"8 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol with any amendments, informed consent, and other information that required preapproval were reviewed and approved by the investigational center ethics committee or institutional review board in China as required.Written informed consent was obtained from each patient before performing any study-specific procedures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BW is an employee of Beijing Novartis Pharma Co., Ltd. All other authors have no conflict of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"219"}}